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ABSTRACT 
The MA-10 Cell Line as a Model of insl3 Regulation and Leydig Cell Function 
Mary Elizabeth Strong 
Leydig cells produce testosterone in response to luteinizing hormone (LH) via the 
cyclic adenosine monophosphate (cAMP)/protein kinase A pathway.  Additionally, these 
cells are responsible for producing insulin-like peptide 3 (INSL3), a peptide hormone that 
is essential for testicular descent.  The insl3 promoter in Leydig cells can be activated by 
cAMP through the transcription factor Nur77, which has also been shown to regulate the 
promoters of the steroidogenic enzymes, cyp17 and 3β-hsd.  While the mechanism of LH 
action on testosterone production is well characterized, the effect of LH on insl3 
abundance has yet to be shown directly.  The MA-10 Leydig cells treated with hCG 
exhibited a transient and robust increase in nur77 mRNA, while insl3 mRNA abundance 
remained unchanged.  Further, cAMP failed to affect insl3 mRNA, though nur77 mRNA 
abundance was significantly increased.  Inhibition of LH-receptor-linked signal 
transduction pathways in the presence of hCG implicated multiple signaling networks in 
the regulation of both insl3 and nur77.  Treatment with hCG or cAMP did not affect the 
abundance of 3β-hsd mRNA.  Interestingly, though the MA-10 cell line has been 
reported to lack CYP17 activity and mRNA and so produce progesterone instead of 
testosterone, cyp17 mRNA was present and inducible by hCG and cAMP.  The addition 
of hCG, testosterone, nor the combination of hCG and testosterone affected insl3 mRNA 
abundance.  Though hCG consistently increased nur77 mRNA abundance, the addition of 
testosterone did not enhance the effects of hCG. Collectively, these results indicate that 
insl3 is regulated by factors other than LH/CG and cAMP in the MA-10 cell line.   
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CHAPTER 1 
Literature Review 
1.1 Introduction 
  The Leydig cells of the testes mediate male sexual development through the 
production of two hormones: testosterone and insulin-like peptide 3 (INSL3).  During 
fetal development, testosterone is essential to the development of the external genitalia, 
the masculinization of the male duct system and the descent of the testes into the scrotum.  
During puberty, testosterone promotes further masculinization and initiates 
spermatogenesis and in adults, testosterone maintains spermatogenesis [1].  INSL3, also 
produced by the Leydig cells of testes, is essential for normal testicular descent to occur 
in fetal life and serves as a germ cell survival factor in adulthood [2, 3].  The descent of 
the testicles into the scrotum is a vital step in normal male sexual development in most 
mammalian species, as the scrotum provides a temperature that is 2-8°C lower than the 
body cavity, which is essential for maintenance of normal spermatogenesis and fertility 
[4, 5].  Cryptorchidism, or the failure of one or both of the testes to descend into the 
scrotum, is a common congenital abnormality that affects 2-8% of human male neonates 
[6].  Retention of the testes in the body cavity and their maintenance at that higher 
temperature is not only detrimental to fertility, but can also increase the risk of 
developing testicular cancer [7, 8].  The potential causes of cryptorchidism remain to be 
elucidated, in part because the intricate network of intra- and intercellular signaling 
pathways that mediate testicular descent have yet to be fully characterized.  The objective 
of this review is to detail the factors that have been identified as modulators of testicular 
descent in an effort to highlight those areas that still warrant investigation. 
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1.2 Sexual Development of Male Mammals 
The fundamental determinant of the male sex in mammals is the inheritance of a 
Y-chromosome at the time of fertilization.  The Y-chromosome contains the sex-
determining region Y (SRY) gene which, when activated, initiates testis development [9-
11].  Sertoli cells are the first cell type to differentiate in the developing gonad and are 
thought to be responsible for inducing further differentiation of the testis.  These events 
include the regression of the Müllerian ducts mediated by anti-Müllerian hormone 
(AMH), development of the testicular cords and interstitium and the differentiation of 
Leydig cells [9].  Once the Leydig cells have differentiated and are capable of hormone 
production and secretion, further virilization of the male reproductive tract ensues.  As 
the Müllerian ducts regress, the Wolffian ducts develop and eventually differentiate into 
the epididymis, vas deferens and seminal vesicles under the control of Leydig cell-
derived testosterone [1, 12].  Subsequent to those events, further masculinization such as 
the development of external genitalia and descent of the testes into the scrotum completes 
the in utero portion of male sexual development, with further developmental and 
hormonal changes taking place during puberty [11, 13]. 
 3 
1.3 Development of the Hypothalamic-Pituitary-Gonadal Axis:   
 The hypothalamic-pituitary-gonadal (HPG) axis is the central control entity for 
sexual development, differentiation and the reproductive functions therein.  Gonadotropin 
releasing hormone (GnRH) is secreted by the hypothalamus in a pulsatile manner into the 
hypothalamic-hypophyseal portal system, a specialized capillary network that is 
connected to the pituitary gland.  This network prevents GnRH from traveling through 
the systemic circulation, making the pituitary the primary target of this hormone.  
Gonadotropic cells in the anterior pituitary express the GnRH receptor and produce 
follicle-stimulating hormone (FSH) and luteinizing hormone (LH) in response to GnRH 
stimulation.  FSH and LH are glycoprotein hormones that bind to their individual G-
protein coupled receptors (GPCR) on testicular Sertoli and Leydig cells to regulate 
spermatogenesis and steroidogenesis [1].  
During gestation, the hypothalamus is the first component of the HPG system to 
develop.  Initial GnRH production coincides with the development of the anterior 
pituitary.  Interestingly, the onset of testosterone synthesis precedes the onset of LH 
synthesis by the pituitary and the expression of the LH receptor by the Leydig cells, 
suggesting that initial testosterone synthesis may be independent of gonadotropin 
stimulation [14, 15].  
The HPG axis is auto-regulated via a negative feedback mechanism.  This 
regulatory mechanism is thought to be the last component of the HPG axis to develop 
[15].  As gonadotropin hormones from the pituitary and steroid hormones from the 
gonads reach threshold levels in the circulation, GnRH secretion from the hypothalamus 
will decrease.  In turn the expression of GnRH receptor and LH and FSH secretion will 
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be down regulated at the pituitary level [1].  A similar mechanism exists at the level of 
the Leydig cell.  When exposure to LH is prolonged or highly concentrated, the Leydig 
cell will compensate in a number of ways, including internalizing and degrading the 
luteinizing hormone receptor (LHR)-LH complex, effectively preventing the cell from 
responding to LH stimulation [16], by decreasing the rate of transcription of the LHR 
gene and by increasing the rate at which LHR mRNA is degraded [17]. 
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1.4 Leydig Cell Development and Differentiated Function  
Leydig cells reside in the interstitial space between the seminiferous tubules, 
closely associated with the vasculature of the testes because of their function as hormone-
secreting endocrine cells [18].  During gestation, after the testis has differentiated into the 
specialized compartments of the testicular cords and interstitium, testicular mesenchymal 
stem cells differentiate into fetal Leydig cells [15, 19, 20].  This fetal population of 
Leydig cells express enzymes involved in steroidogenesis, have the machinery necessary 
for hormone secretion and produce androgens required for fetal masculinization [15, 19].  
In addition to androgen, fetal Leydig cells also produce the peptide hormone insulin-like 
peptide 3 (INSL3), which also plays a role male sexual development as a mediator of 
testicular descent [21].  Interestingly, fetal Leydig cells are not the precursors for the 
adult Leydig cells and will eventually undergo involution after the male genitalia have 
developed [15]; adult Leydig cells originate from stem cells present in the testes after 
birth [20].  
The postnatal development of Leydig cells is characterized by undifferentiated 
mesenchymal stem cells progressing from a multipotent stem cell to a Leydig cell 
progenitor to an immature Leydig cell and finally differentiating into an adult Leydig cell 
(Reviewed in [20, 22]).  The initial differentiation of mesenchymal stem cells into Leydig 
cell progenitors occurs in the rat between postnatal days 10 and 28 [20, 23].  Leydig cell 
progenitors produce proteins that are exclusive to Leydig cells and are essential for 
steroid biosynthesis.  The smooth endoplasmic reticulum (SER) contains the enzymes 
necessary for steroidogenesis including, 3β-hydroxysteroid dehydrogenase (3β-HSD), 
cytochrome P450 17α-hydroxylase/C17-20 lyase (CYP17) and 17-ketosteroid 
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reductase/17β-hydroxysteroid dehydrogenase (17-KSR/17β-HSD).  While the SER is 
virtually absent in Leydig cell progenitors, they still possess some 3β-HSD activity and 
are capable of producing androgens (Reviewed in [20]).  This may be due a 
mitochondrial source of steroidogenic enzymes during this stage of Leydig cell 
development [20].   While Leydig cell progenitors do express receptors for androgen, 
estrogen and insulin-like growth factor-1 (IGF-1), they only express the extracellular 
domain of the LHR and are therefore insensitive to LH stimulation [20].  
Because of the lack of the intracellular domain of the LHR, other factors are 
implicated in the development and differentiation of Leydig cell progenitors into 
immature Leydig cells [20].  IGF-1 stimulates proliferation of mesenchymal stem cells, 
Leydig cell progenitors and immature Leydig cells.  The surrounding Sertoli cells and 
testicular macrophages secrete proteins and cytokines that stimulate proliferation and 
differentiation of Leydig cells [20].  IGF-1 appears to play a role in Leydig cell 
maturation, as igf-1 knockout mice possessed reduced numbers of Leydig cells, 
attributable to an aberration in differentiation and proliferation of Leydig cell progenitors.  
These igf-1 -/- mice also exhibited reduced testosterone levels, and reduced expression of 
several enzymes involved in steroidogenesis, including steroidogenic acute regulatory 
protein (StAR), CYP11A1 and CYP17A1 [24].   
Leydig cell progenitors differentiate into immature Leydig cells between postnatal 
day 28 and 56 in the rat [20, 23].  Immature Leydig cells have a well-developed SER and 
exhibit a greater amount of 3β-HSD activity than Leydig cell progenitors.  They also 
contain numerous cytoplasmic lipid droplets, thought to be the primary source of 
 7 
cholesterol for steroidogenesis.  Immature Leydig cells divide once before differentiating 
into adult Leydig cells [20, 22].   
At the onset of puberty, approximately postnatal day 56 in the rat, immature 
Leydig cells differentiate to create the adult population of Leydig cells.  Adult Leydig 
cells are larger and rarely proliferate.  Rather the Leydig cell population is maintained at 
a relatively steady state, with Leydig cell death being balanced out by Leydig cell 
replenishment from stem cell populations within the testes [22].  The primary function of 
this population of Leydig cells is to respond to LH stimulation by producing testosterone 
to initiate spermatogenesis.  Adult Leydig cells, therefore, express a greater amount of 
functional LHR.  Additionally, the lipid content of this population of Leydig cells is 
markedly lower than that of their immature predecessors.  These cells instead derive 
cholesterol necessary for steroidogenesis from serum lipoproteins or synthesize it de novo 
[20, 22, 25].  Though the timing of postnatal Leydig cell differentiation has been most 
fully characterized in the rat, a similar progression is thought to be present in the human 
and other species.  
Steroidogenesis by the adult Leydig cell is characterized by a series of enzymatic 
reactions that catalyze the conversion of cholesterol into testosterone. Acquisition of 
cholesterol by the Leydig cell is achieved either via low-density lipoprotein (LDL) and 
high-density lipoprotein (HDL) receptors or synthesized de novo.  Subsequently, it is 
transferred to the inner mitochondrial membrane under the regulation of StAR.  
Cholesterol is then converted to pregnenolone by CYP11A1.  Pregnenolone is exported 
to the SER where it is converted to progesterone by 3β-HSD.  Then, progesterone is 
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converted to 17(OH)-progesterone and further to androstenedione by the dual function 
enzyme CYP17.  Androstenedione is then converted to testosterone by 17β-HSD [1, 26]. 
Testosterone travels to peripheral tissues via the blood stream and exerts its 
effects through the androgen receptor (AR).  At the level of the testes, testosterone 
regulates spermatogenesis, Sertoli cell function and can exert an autocrine effect on the 
Leydig cell through the AR.  Peripheral biological effects of testosterone include 
regulation of metabolic processes, male secondary sex characteristics and its own 
production through the negative feedback mechanism present in the HPG axis [1, 27].   
Testosterone can be further converted to estrogen by the enzyme cytochrome 
P450 aromatase (CYP19).  The Leydig cells are the primary source of testicular estrogen, 
though CYP19 is also present Sertoli and germ cells.  Further, CYP19 has been detected 
in many peripheral tissues including adipose, liver, brain, kidney and skeletal muscle 
[26].  Testicular estrogen has been shown to regulate fluid transport within the male 
reproductive tract to effectively concentrate sperm before it enters into the epididymis.  In 
male estrogen receptor-α (ERα) knockout mice, fluid reabsorption was impaired, 
resulting in infertility as the mice progressed in age [28].  Further, testicular estrogen 
participates in negative feedback regulation at the level of the hypothalamus and pituitary 
[1].          
In addition to estrogen, testosterone can also be converted to dihydrotestosterone 
(DHT) in the Leydig cells by the enzyme 5α-reductase [26].  DHT plays a role in 
negative feedback regulation of the HPG axis and is crucial for the masculinization of the 
male reproductive tract, including the development of the urethra, prostate and external 
genitalia [29]. 
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1.5 Testicular Descent 
Testicular descent is a critical process in mammalian male sexual development 
and is completed in humans and horses before birth; while in rodents, descent is 
completed postnatally [8, 30-33].  Though the timing of events differs between species, 
the process of testicular descent is essentially the same.  The testes migrate from high in 
the abdomen, adjacent to the kidneys, to the extra-abdominal location in the scrotum.  
The extra-abdominal position allows the testes to be maintained at a temperature 2-8°C 
lower than that of the body cavity [4, 5].  This lower temperature is essential for 
maintaining spermatogenesis, fertility and gonadal function [4].  In several mammals 
including elephants, hyraxes, edentates, such as anteaters and armadillos, insectivores, 
such as sloths, and cetaceans, such as whales, the testes remain in the abdomen, without 
consequence to their reproductive capability.  This is theoretically due to an inherently 
lower core body temperature, or the presence of alternative cooling mechanisms [34]. 
 Testicular descent can be delineated into two phases, termed the transabdominal 
and inguinoscrotal phases.  During the first or transabdominal phase, testes migrate from 
the level of the kidneys to the inguinal ring.  This is achieved by concurrent regression of 
the cranial suspensory ligament (CSL) and development of the gubernaculum, the 
ultimate result of which is the testes moving to the level of the inguinal ring [2].  
In the female, the development of the CSL and the regression of the 
gubernaculum keep the ovaries adjacent to the kidney; while in the male, CSL regression 
is essential to allow the gubernaculum to draw the testes downward [2].  The regression 
of the CSL is an androgen-dependent process, as evidenced by the persistence of the CSL 
and the testes remaining high in the abdominal cavity in both androgen-insensitive mice 
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that possess a loss-of-function mutation of the AR and in normal rats that were fetally 
exposed to an AR antagonist [35, 36].   The gubernaculum is attached firmly to both the 
testes and the area near the inguinal ring and the outgrowth and subsequent regression of 
the gubernaculum pulls the testes down toward the inguinal ring [37].  This process is 
regulated by INSL3, a peptide hormone produced by the Leydig cells of the testes.  When 
INSL3 binds to its receptor on gubernacular cells, the proliferation and differentiation of 
the gubernaculum ensues, ultimately resulting in the anchoring of the testes at the 
inguinal ring [2, 38-40].  
During the second or inguinoscrotal phase, the scrotum is hollowed out by the 
process vaginalis, creating a space for the incoming testes and the gubernaculum moves 
through the inguinal ring, drawing the testes into the scrotum [2, 7, 41].  The movement 
of the testes through the inguinal ring is driven, in part, by the shrinking of the 
gubernaculum, pulling the testes into the scrotum and in part by mounting intra-
abdominal pressure, pushing the testes through the inguinal ring [7, 33].  The increase in 
intra-abdominal pressure is thought to stem from an increase in the size of the viscera, 
fetal respiratory efforts, and abdominal wall contraction [37].  The inguinoscrotal phase is 
mediated by testosterone as evidenced by the presence of the AR in gubernacular cells 
and the fact that the gubernaculum does not migrate beyond the inguinal region in 
gonadotropin-deficient and androgen-resistant animals [7, 42, 43]. 
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1.6 Cryptorchidism  
Cryptorchidism, or the failure of one or both of the testes to descend into the 
scrotum is a common developmental abnormality, affecting 2-8% of human male 
neonates and stallions [6]. Interestingly, many congenital cryptorchid cases have been 
shown to correct themselves within the first few months after birth, so the prevalence of 
this condition is reduced to 1-2% in boys between 3 and 12 months of age [7, 8].  This 
disorder has been shown to have a detrimental effect on fertility due to the maintenance 
of the testes at the higher temperature associated with the body cavity, compared to the 
relatively lower temperature in the scrotum [8].  Infertility is thought to stem from a 
degeneration of both steroidogenesis and germ cell production, each of which begin to 
show signs of deterioration within the first 6 months after birth in cryptorchid boys [7].  
In addition to the impairment of fertility associated with this disorder, the risk of 
developing testicular cancer has been suggested to increase by about 5 to 10-fold in the 
cryptorchid individual [7].  Interestingly, cryptorchidism has been reportedly associated 
with only 5% of testicular cancer cases, with bilaterally cryptorchid individuals running a 
greater risk of developing testicular malignancy than unilaterally cryptorchid individuals 
(Reviewed in [4, 7, 8]). Germ cell degeneration within the cryptorchid testes is thought to 
be the cause of this increased risk as developing spermatids in the testes are the most 
susceptible to heat and will either die or develop into spermatozoa with damaged DNA, 
potentially contributing to the development of a testicular malignancy [4].  
Though a singular cause of cryptorchidism has not been identified, several 
potential causes and risk factors have been investigated.  Cryptorchidism can occur as a 
single abnormality in healthy individuals or as a counterpart to other disorders such as 
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abnormal midline differentiation, renal and urinary tract abnormalities, hypospadias, and 
malformations of the central nervous system [8].  Furthermore, in utero exposure to 
phthalate monoesters and persistent organochorlides has been linked to cryptorchidism 
[8, 33].  Studies on the heritability of cryptorchidism have indicated that a child having a 
cryptorchid brother is more likely to also be cryptorchid than a child with a cryptorchid 
father, highlighting potential significance of the in utero environment [33].  Additionally, 
monogenetic causes of cryptorchidism have been investigated and though some 
cryptorchid cases may be attributed to an alteration in a given gene, those mutations do 
not account for the greater part of cryptorchid cases [33].  Collectively, these data suggest 
that there is no singular cause of cryptorchidism, but that the root of this disorder is as 
distinct as the individuals in which it occurs.  
Treatment options vary with location of the testes and species.  In humans, the 
testicles have reached their extra-abdominal location in the scrotum at the time of birth.  
Treatment options include orchidopexy, a surgical procedure in which the retained testis 
or testes are manually descended and fixed in the scrotum, or hormone therapy with hCG 
or GnRH, which has had marginal success, with about 10-20% of boys experiencing full 
testicular descent [7].  Correction of the cryptorchid phenotype, either manually or 
hormonally, can rescue fertility.  For example, adult men with bilaterally cryptorchid 
testes are azoospermic, but after orchidopexy 28% of cases display a normal sperm count 
[8], though it seems that timely surgical intervention optimizes the chance for a full 
recovery of spermatogenic abilities, as degeneration of germ cells occurs within 6-12 
months after parturition [7].  In stallions, the most common treatment of cryptorchidism 
is castration, which can be an invasive procedure depending upon the location of the 
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testes.  Hormone therapies have not been thoroughly investigated in horses.  Treatment of 
cryptorchid stallions with hCG resulted in increased testosterone production by these 
individuals, though it did not have effect on the location of the testes [44]. 
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1.7 Luteinizing Hormone and Chorionic Gonadotropin 
LH is a heterodimeric peptide hormone composed of a common gonadotropin α-
subunit and an LH-specific β-subunit [45].  Similar to GnRH secretion from the 
hypothalamus, LH is secreted from the anterior pituitary in a pulsatile fashion, with 
pulses occurring every 3-6 hours [46].  In the male, LH stimulates testosterone synthesis 
by testicular Leydig cells in addition to regulating its own production as part of the 
negative feedback system present in the HPG axis.   
In rodents, initial testosterone production is gonadotropin-independent as 
steroidogenesis begins before the onset of LH secretion in these models [14].  Once LH is 
present, however, there is a significant increase in LHR expression and testosterone 
production by the Leydig cells [15].  In contrast, chorionic gonadotropin is thought to 
stimulate fetal steroidogenesis in humans [14]. 
Chorionic gonadotropin (CG) is a glycoprotein hormone produced by the placenta 
during gestation to maintain pregnancy in only humans and horses [47, 48].  CG is 
composed of a common gonadotropin α-subunit and a β-subunit that is about 80% 
homologous with the LH β-subunit [49] though CG has a greater molecular weight and is 
more heavily glycosylated than LH.  More importantly, the receptor for CG is also the 
LHR, though CG binds this receptor with a relatively higher affinity than LH and has a 
longer half life in circulation [45, 47].  Despite the higher affinity for the LHR, CG is 
capable of eliciting effects equivalent to that of LH through this receptor.  Further, human 
CG (hCG) is more easily purified from the placenta than LH is from the pituitary and is a 
commonly used as an LH analog for research purposes [17].  In the human, the main 
gonadotropic stimulus in utero is thought to be hCG as synthesis begins early in gestation 
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and reaches a maximum in weeks 11-14; this is also the time when the testosterone 
content of the testes is at a maximum [14].  
The most well characterized mechanism by which LH induces steroidogenesis by 
the Leydig cell is through the LHR-associated cyclic adenosine monophosphate/protein 
kinase-A (cAMP/PKA) signaling cascade.  The LHR is a 7-transmembrane domain G-
protein coupled receptor (GPCR), located on the plasma membrane of the Leydig cell.  
When LH binds the extracellular domain of the LHR, the intracellular portion of the 
receptor undergoes a conformational change, activating a stimulatory G-protein (Gs), 
which in turn activates the enzyme adenylyl cyclase.  This enzyme catalyzes the 
conversion of ATP into cAMP, which in turn activates cAMP-dependent protein kinase-
A (PKA) [1, 50].  PKA then phosphorylates target proteins involved in testosterone 
production, such as the transcription factor SF-1, which then activates the transcription of 
steroidogenic enzymes, such as StAR protein [51, 52]. 
Though the LHR is undoubtedly associated with the cAMP/PKA pathway, several 
other pathways and factors have been shown to regulate steroidogenesis in response to 
LH.  LHR and subsequent cAMP/PKA activation has been shown to activate the 
epidermal growth factor receptor (EGFR) and the associated mitogen-activated protein 
kinase (MAPK) pathway in MLTC-1 mouse Leydig cells.  The transactivation of the 
EGFR by this mechanism was necessary for gonadotropin-induced steroidogenesis in this 
Leydig cell line [53].  The LHR has also been shown to activate the phopholipase C 
(PLC) pathway in the mouse fibroblast L cell line stably transfected with the murine LHR 
[54].  The down stream effector of PLC, protein kinase C (PKC) has been indirectly 
implicated in regulating LH-stimulated steroidogenesis as the presence of phorbol esters, 
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which stimulate PKC activation, stimulated testosterone production in porcine Leydig 
cells [52, 55].   
The transcription factor Nur77, discussed in detail later in this review, has been 
shown to regulate the promoters of several enzymes involved in steroidogenesis 
including CYP17 and 3β-HSD [56, 57].  Inhibiting PKC in K28 Leydig cells and treating 
with LH abrogated the response to LH as evidenced by the 76% decrease in Nur77 
mRNA compared with LH induction alone [58].   The phosphatidylinositol 3/protein 
kinase B (PI3K/PKB) pathway has also been implicated as an effector of LHR activation, 
as inhibition of this pathway abated the LH-dependent increase in Nur77 by 70% [58]. 
 17 
1.8 Insulin-like Peptide 3   
Insulin-like peptide 3 (INSL3), a critical mediator of testicular descent, is a 
peptide hormone produced by the Leydig cells of the testes [31].  During fetal life, INSL3 
is produced by the fetal Leydig cells and is essential for the completion of the 
transabdominal phase of testicular descent.  In postnatal life, INSL3 levels increase 
significantly during puberty and INSL3 acts as a germ cell survival factor in both males 
and females [3, 59-61].    
The necessity of INSL3 in the transabdominal phase of testicular descent has been 
demonstrated by transgenic insl3 knockout mice, in which all males were infertile and 
bilaterally cryptorchid, with the testes located high in the abdomen due to the failure of 
gubernacular development [2, 41].  Female AR and insl3 knockout mice mirror the 
phenotype of the wild-type female [41].  In addition, when INSL3 is overexpressed in 
pancreatic beta cells of insl3 knockout mice, testicular descent is restored in the male and 
in the female, the ovaries descend to an extra abdominal location [41].  The essential 
nature of INSL3 in the development of the gubernaculum and therefore the process of 
testicular descent suggests that a mutation in the insl3 gene or in that of its receptor may 
contribute to cryptorchidism.  However, the occurrence of insl3 mutations in patients 
with alterations in testis descent is reportedly low, between 1.4-2.2% [62, 63].  Further, 
the cumulative prevalence of mutations in the INSL3 receptor in cryptorchid individuals 
is only 2.9% [64].  
INSL3 is also expressed in ovarian thecal and luteal cells and is thought to play a 
role in germ cell maturation.  In cultured preovulatory follicles, treatment with INSL3 
induced meiotic progression of arrested oocytes [3].  Further, female insl3 knockout mice 
 18 
exhibit impaired fertility and an elongated estrous cycle, though reproductive tract 
morphology and embryonic implantation were normal, indicating that INSL3 may help 
regulate the estrous cycle [38].  These results are not consistently observed; Zimmerman 
et al. (1999) found that insl3 female knockout mice not only exhibit a normal estrous 
cycle but also are capable of reproducing, without any apparent abnormalities noted in 
the offspring.  
The receptor for INSL3, the leucine-rich repeat-containing G-protein-coupled 
receptor 8 (LGR8), is located on the membrane of gubernacular cells [65].  Mice in 
which the LGR8 gene has been deleted are phenotypically similar to insl3 knockout mice, 
in that the testes are located high in the abdomen, adjacent to the kidneys, due to the lack 
of gubernacular development in these animals [40].  These data highlight the essential 
nature of the INSL3/LGR8 ligand-receptor system in mediating the transabdominal phase 
of testicular descent.  In gubernacular cells, cAMP levels have been shown to 
significantly increase in response to INSL3, implicating the cAMP/PKA signaling 
pathway in facilitating the growth and regression of the gubernaculum during the first 
phase of testicular descent [65]. 
LGR8 has also been detected in the germ cells of the testes and ovary, indicative 
of the continued and paracrine effects of INSL3 into adult life as a germ cell survival 
factor [3, 60].  Interestingly, it has been shown that treatment of cultured preovulatory 
follicles with INSL3 led to a decrease in intra-oocyte cAMP levels, which allowed those 
oocytes to resume meiosis.  Further, the inhibitory Gi protein was implicated in this 
decrease in cAMP as concurrent treatment with a Gi protein inhibitor impaired the ability 
of INSL3 to induce meiotic progression of oocytes [3].     
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Previous research in our lab has indicated that there is a lower abundance of 
INSL3 protein present in the retained as opposed to descended testis in unilaterally 
cryptorchid horses as determined by western blotting (Peterson et al., unpublished data).  
These results were congruent with those of Klonisch et al. (2003), who compared INSL3 
levels between bilaterally cryptorchid horses and horses where both testicles were 
descended.  The discrepancy in INSL3 production by the testes of unilaterally 
cryptorchid horses was of particular interest because two different levels of this hormone 
were present in the same tissue in the same animal and led us to investigate the factors 
that regulate the production of INSL3 by the Leydig cells of the testes.
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1.9 INSL3 Regulation  
Several hormone cues, signal transduction components and transcription factors 
have been identified as having a role in mediating INSL3 production.  Included in this 
regulatory milieu are LH/CG, testosterone, estradiol, the second messenger cAMP and 
the nuclear receptors SF-1 and Nur77.  Though the individual effect of these regulatory 
components has been investigated in part, the comprehensive network of signals that 
ultimately regulates INSL3 production has yet to be fully defined. 
LH/CG has been heavily implicated as a regulator of INSL3 production.  For 
example, hCG has been shown to increase ovarian insl3 mRNA abundance when 
administered by injection to female rats [3].  Additionally, the second messenger cAMP, 
which is classically associated with the LHR has been shown to increase insl3 mRNA 
abundance in the MA-10 cell line [66].  Further evidence to suggest that luteinizing 
hormone may stimulate INSL3 production comes from transgenic mouse models.  In 
transgenic hpg mice that lack a functioning HPG axis, insl3 mRNA levels are 
significantly lower than their wild-type counterparts but when supplemented with hCG, 
wild-type levels of insl3 are restored.  LHR knockout mice are bilaterally cryptorchid, 
infertile and exhibit significantly lower abundance of insl3 mRNA than their wild-type 
counterparts [67, 68].   Testosterone replacement therapy successfully restores 
gubernacular development and testicular descent in these animals [67, 68], though 
interestingly, did not increase insl3 mRNA abundance back to wild-type levels [68].  In 
the MA-10 Leydig cell line, testosterone has been shown to induce INSL3 production 
through the actions of the AR [69] and estradiol has an inhibitory effect on INSL3 
production which can be abrogated by the actions of testosterone [70].  
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Steroidogenic factor 1 (SF-1), a prominent transcription factor involved in sexual 
development expressed in the hypothalamus and anterior pituitary gland, plays an 
essential role in the development of the HPG axis [9].  SF-1 has also been detected in 
Leydig and Sertoli cells, thecal and granulosa cells and adrenocortical cells [71].  Further 
SF-1 has been shown to bind to and transactivate the insl3 promoter in MA-10 Leydig 
cells.  Experiments in which insl3 promoter reporter gene deletion constructs were 
transfected into MA-10 cells indicated that the -157 to -53bp segment of the insl3 
promoter contains the putative response element for SF-1 and is sufficient for inducing 
the expression of the reporter gene in this context [72].  
The transcription factor Nur77 is termed an orphan nuclear receptor, as it binds no 
known ligand.  Nur77 is expressed in the testes and regulates the expression 
steroidogenic enzymes, including CYP17 and 3β-HSD [56, 57].  Further, the expression 
of nur77 itself is induced in response to LH and cAMP in Leydig cells [56, 58].  In 
addition to the regulation of steroidogenic enzyme genes, Nur77 has been implicated in 
regulating the insl3 gene.  When MA-10 cells were cotransfected with luciferase reporter 
vectors containing the -1137bp to +11bp region of the human insl3 promoter and 
increasing concentrations of Nur77 expression vectors, a dose-dependent increase in 
luciferase activity was observed, indicating that Nur77 is able to activate the human insl3 
promoter.  Experiments in which various 5’ deletion constructs of the -1137bp to +11bp 
region of the human insl3 promoter and Nur77 expression vectors were cotransfected into 
MA-10 cells, indicated that the -322bp to -93bp segment of this promoter contains the 
Nur77 response element.  Nur77 binding to this response element was confirmed by 
electromobility shift assay.  Because Nur77 has been shown to increase in response to LH 
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[58], and there is substantial evidence to suggest a similar response by insl3, it was 
hypothesized that Nur77 may be a downstream effector of the LHR and might be 
involved in regulating insl3 production as well.  MA-10 cells were cotransfected with 
Nur77 expression vectors and either a wild-type human insl3 reporter vector or one with 
a single mutation present in the Nur77 response element.  These cells were then treated 
with cAMP, a second messenger known to be associated with the LHR.  In this context, 
treatment with cAMP significantly increased the expression of the reporter gene in those 
cells that were transfected with the wild-type insl3 promoter.  This effect of cAMP was 
completely abrogated in those cells that contained the vector with the mutated Nur77 
response element.  These data collectively indicated that cAMP is capable of activating 
the insl3 promoter through the actions of Nur77 [66].  
The activity of Nur77 and subsequent ability of this transcription factor to bind to 
and activate a target promoter appears to be regulated by posttranslational modifications.  
In MA-10 cells transiently cotransfected with a human insl3 reporter vector and a nur77 
expression vector, a significant increase in insl3 promoter activation was observed.  In 
this context, Nur77 was found to require protein phosphatase activity to activate the insl3 
promoter, as treatment with a protein phosphatase inhibitor completely abolished Nur77-
induced insl3 promoter activation, suggesting that Nur77 may require dephosphorylation 
to be active [73].  In adrenal medullar cells, phosphorylation of Nur77 at Ser340 and Ser 
350 has been shown to decrease Nur77-DNA binding affinity and its ability to activate 
transcription, as these residues are located within the DNA-binding domain [74].  In other 
reporter vector experiments, adrenal cortical cells were cotransfected with a Nur77 
response element reporter vector and an expression vector containing the catalytic 
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subunit of PKA.  There was a significant increase in the transcription of the reporter gene 
in the presence of the PKA expression vector.  Additionally, cells transfected with the 
same Nur77 response element reporter vector and subsequently treated with forskolin, an 
adenylyl cyclase activator, also exhibited a significant induction of the Nur77-response 
element driven reporter gene.  Furthermore, it appears that activation of the cAMP/PKA 
pathway promotes Nur77 binding to DNA in these adrenal cortical cells by inducing the 
dephosphorylation of Ser316.  When adrenal cortical cells were cotransfected with the 
Nur77 response element reporter vector mentioned above, and an expression vector 
containing either the wild-type Nur77 or a Ser316Ala Nur77 mutant, which cannot be 
phosphorylated, the mutant form of Nur77 displayed a greater basal transcriptional 
activity than its wild-type counterpart.  This effect was enhanced by the addition of PKA, 
implicating Nur77 as a down stream effector of the cAMP/PKA signal transduction 
pathway [75].  However, the mechanism of dephosphorylation, mainly the identity of the 
protein phosphatase that is required for the activation of Nur77 in this context and how it 
is linked to the cAMP/PKA pathway, remains to be elucidated. 
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1.10 MA-10 Cell Line: 
Cell models are useful and convenient tools for studying the function of a given 
cellular system or response.  The goal of using such models is to accurately mimic in vivo 
function in a controlled setting, providing a practical alternative to whole animal studies.  
Cell culture methods of studying individual cell type function is particularly 
advantageous in that the environment in which the cells are maintained is easily 
controlled and manipulated, facilitating the assessment of a cellular response to a 
specified concentration of a treatment for an allotted amount of time.   
Two widely used cell models are primary cell isolates and immortal cell lines.  
Though primary cell cultures are often regarded as bearing a greater similarity to in vivo 
function because of their immediate isolation and use from the tissue, they tend to be 
laborious to isolate, may contain other cell types native to the tissues from which they 
were isolated and are only capable of a limited number of cellular divisions.   Immortal 
cell lines are homologous populations of cells that are theoretically capable of an infinite 
number of mitotic events.  These types of cell lines are more stable, consistent and easier 
to maintain in culture than primary cells of the same type.  The immortality of a cell line 
is either due to their derivation from a tumor, or their transformation with an 
immortalizing antigen [76].  The benefit and detriment of using a cell line lies with the 
fact that theoretically, a single cell type is present in each culture.  While this feature 
allows for the assessment of the effects of a treatment on only the cell type of interest 
without the complication of other cell types and signals that are present in tissue samples, 
it removes an individual cell system from the potentially more biologically relevant in 
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vivo context, where cells are regulated by cell-to-cell interactions, other cell types and 
other signals [76].   
The inherent differences between cell lines and primary cultures lie with the fact 
that most cell lines are isolated from tumors, which confers their ability to continuously 
proliferate unlike primary cells.  Immortal cell lines isolated from tumors can exhibit 
differential expression of any number of genes and that must be considered when using 
them as a model of normal in vivo function.  For example, one of the hallmarks of an 
immortal cell line is the ability to continually divide.  This is often due to the suppression 
of the p53 gene, which encodes a protein that can prevent a cell from entering the cell 
cycle if that cell’s DNA is damaged [50].  Inactivation of this gene allows cells with 
mutated or damaged DNA to enter the cell cycle and proliferate.  Indeed, mutations in the 
p53 gene are present in roughly half of all human cancers [50].  Therefore, within an 
immortal, tumor cell line, there may be any number of genes that harbor mutations not 
present in normal cells.   
Primary Leydig cells are difficult to isolate because of the relatively low number 
of Leydig cells present in the testes.  In culture, primary Leydig cells tend to lose 
differentiated function by becoming less responsive to gonadotropin stimulation and 
losing their capacity for steroidogenesis [77].   
The MA-10 Leydig cell line was derived from the M5480 murine Leydig cell 
tumor [78].  These cells are gonadotropin responsive and produce INSL3.  This cell line 
is a frequently utilized model of Leydig cell function, LH/CG activity, second messenger 
response, INSL3 production and steroidogenesis [77].  MA-10 cells are reported to 
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produce progesterone instead of testosterone as a steroidogenic endpoint because of their 
apparent lack of cyp17 mRNA and activity [77].   
MA-10 cells utilize several different means to regulate the availability of the LHR 
at the plasma membrane and hence, the ability of the cells to respond to LH/CG.  One 
mechanism by which these cells control the response to gonadotropin stimulation is a 
rapid internalization of the LHR.  This occurs more quickly in MA-10 cells than in 
primary Leydig cells for unknown reasons [77].  The fate of hCG-bound LHR has been 
studied in MA-10 cells.  It has been shown that as the receptor-hormone complexes are 
internalized via receptor-mediated endocytosis and accumulate in lysosomes, hCG is 
dissociated from its receptor and degraded within the lysosome.  In this study, it was not 
empirically determined whether the LHR is also degraded [79].  It still remains to be 
shown whether the LHR down-regulation is due to degradation of that receptor once it is 
internalized, or if the LHR is only temporarily sequestered away from the membrane.  In 
all likelihood, it is a combination of these mechanisms that regulate the abundance of the 
LHR on the membrane of MA-10 cells.  Further, both LH/CG and cAMP have been 
shown to decrease LHR mRNA abundance, though it is not clear whether this is due to a 
decrease in the transcription of the lhr gene, an increase in the rate of LHR mRNA 
degradation, or a combination of both of these mechanisms [77, 80].    
Over time, MA-10 cells have exhibited a decrease in both adherence to cell 
culture surfaces and proliferative capacity [81].  The reasons behind the noted decrease in 
attachment and proliferation have not been directly investigated, though it is speculated 
that these changes are due to a change in the manufacturing protocols and coatings of cell 
culture plasticware.  This hypothesis is supported by the fact that cells maintained in 
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liquid nitrogen since 1981 exhibit the same alterations and coating plasticware with a 
gelatin solution abrogates both proliferation and adherence issues [81].  MA-10 cells 
have also exhibited a decrease in LHR abundance from that of the parent cells from 
5,000-20,000 receptors/cell (reviewed in [77]) to 600-1,000 receptors/cell.  Because of 
this decrease, MA-10 cells were assessed for their ability to express a recombinant human 
LHR construct as part of an expression vector.  These cells successfully expressed the 
human LHR on the membrane and were capable of binding hCG and responding with an 
increase in cAMP and progesterone production.  The remaining endogenous receptors 
were deemed functionally capable of responding to gonadotropin stimulation as MA-10 
cells transiently transfected with an empty expression vector responded to hCG treatment 
with a significant increase in both cAMP and progesterone production [81].  
 The MA-10 cell line is prevalent in the literature as a model of Leydig cell 
function despite the caveats detailed above.  Because of the reported similarity to the 
whole testicular lysates in terms of expression of insl3 and nur77 [66], this cell line was 
deemed an appropriate model for the current work. 
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1.11 Summary 
 The descent of the testicles into the scrotum is essential for normal male sexual 
development and continued fertility and testicular health throughout sexual maturity.  The 
etiology of cryptorchidism is not well characterized, though differential expression of 
INSL3 in cryptorchid models illustrates the necessity of INSL3 in the process of descent 
and makes it a prime candidate for studying a potential cause of cryptorchidism.  The 
regulation of INSL3 production, however, is not well understood.  A comprehensive 
description of the factors that regulate the insl3 gene is paramount to understanding the 
process of testicular descent.  As hormone therapies have been relatively unsuccessful in 
treating cryptorchidism, an enhanced understanding of the elements that regulate 
testicular descent may allow for the cause of each individual case of cryptorchidism to be 
more accurately defined, which may in turn enhance the selection of a more appropriate 
and useful hormone therapy for each individual case.  Several factors have been 
implicated in INSL3 production and regulation, including LH/CG, the cAMP/PKA signal 
transduction pathway and the transcription factor Nur77.  The following work utilizes 
these known factors and the MA-10 cell line to model and investigate the regulation of 
insl3 mRNA abundance in the Leydig cell.  
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CHAPTER 2 
The MA-10 Cell Line as a Model of insl3 Regulation and Leydig Cell Function 
2.1 Introduction  
Insulin-like peptide 3 (INSL3), a peptide hormone produced by the Leydig cells 
of the testes, is a critical mediator of testicular descent.  Male insl3 knockout mice are 
sterile and bilaterally cryptorchid [1] but when insl3 is overexpressed in the pancreatic β-
cells of these mice, normal testicular descent is restored in the male and in the female, the 
ovaries descend to an extraabdominal location [2].  Though the central role of INSL3 in 
normal sexual development is appreciated, the factors that regulate INSL3 production 
have yet to be comprehensively defined.  
The primary and most well known function of the Leydig cell is to produce 
testosterone in response to luteinizing hormone (LH) binding the G-protein coupled LH 
receptor (LHR) and activating the cyclic adenosine monophosphate/protein kinase A 
(cAMP/PKA) signal transduction pathway.  Several other signal transduction pathways 
have been shown to be associated with the LHR, including the protein kinase B (PKB), 
mitogen activated protein kinase (MAPK) and the protein kinase C (PKC) pathways [3-
5].  The LHR-linked cAMP/ PKA pathway may also regulate the production of INSL3 by 
the Leydig cell as cAMP has been shown to increase insl3 mRNA abundance in the MA-
10 Leydig cell line [6].  In transgenic hpg mice that lack a functioning hypothalamic-
pituitary-gonadal axis, insl3 mRNA levels are significantly lower than their wild-type 
counterparts but, when supplemented with hCG, wild-type levels of insl3 are restored [7]. 
The orphan nuclear receptor, Nur77, is a transcription factor that regulates the 
insl3 promoter and the promoters of several genes involved in steroidogenesis, including 
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the cytochrome p450 17α-hydroxylase (cyp17) and 3β-hydroxysteroid dehydrogenase 
(3β-hsd) promoters [8].  Nur77 has been shown to bind to its response element and 
activate the transcription of a reporter gene when the -1137bp to +11bp region of the 
human insl3 promoter is transfected into MA-10 Leydig cells as part of a reporter gene 
construct in addition to a Nur77 expression vector [6, 9].  Additionally, when MA-10 
cells were transfected with either a wild-type Nur77 response element reporter vector or a 
mutated construct and treated with cAMP, there was a significant induction of the 
reporter gene only in those cells containing the wild-type vector.  In this context, it seems 
that cAMP activates the insl3 promoter through the actions of Nur77 [6].  Further, the 
expression of nur77 itself is induced by LH in Leydig cells and the cAMP/PKA pathway 
promotes binding of Nur77 to DNA in adrenal cortical cells [10, 11].  These results 
indicate that LH working through the cAMP/PKA pathway and the transcription factor 
Nur77 may be the mechanism by which INSL3 is produced by the Leydig cell, though 
this relationship has never been shown directly.   
Recent studies in the MA-10 Leydig cell line indicate that treatment with estradiol 
results in a decrease in insl3 mRNA abundance, with those effects being abrogated by 
testosterone [12].  Treatment of MA-10 cells with testosterone concentrations ranging 
from 1.5 to 1500nM for 36h, resulted in an increase in insl3 mRNA abundance.  Further, 
when the same -1137bp to +11bp segment of the human insl3 promoter is transfected into 
MA-10 cells, as part of a reporter gene construct, transcription of the reporter gene is 
activated in response to 15nM testosterone treatment for 36h.  The addition of an 
androgen receptor (AR) antagonist abrogated the effects of testosterone on both insl3 
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mRNA abundance and insl3 promoter activation, suggesting that testosterone is able to 
exert an autocrine effect on the Leydig cell and regulate insl3 through the AR [13]. 
The MA-10 Leydig cell line was isolated from a murine Leydig cell tumor and 
retained many of the characteristics of normal Leydig cells such as LHR expression, 
INSL3 production and increased steroidogenesis in response to cAMP and LH/CG 
stimulation [14].  This cell line is currently accepted as a model of steroidogenesis and 
Leydig cell function, despite the fact that these cells are reported to lack CYP17 activity 
and therefore produce progesterone instead of testosterone as a steroidogenic endpoint 
[15].  Over time, MA-10 cells have exhibited a decrease in both adherence to cell culture 
surfaces and proliferative capacity, each of which can be addressed by coating 
plasticware with a gelatin solution [16].  They have also exhibited a decrease in LHR 
abundance from that of the parent cells from 5,000-20,000 receptors/cell (reviewed in 
[15]) to 600-1,000 receptors/cell, though the remaining receptors are functionally capable 
of responding to gonadotropin stimulation [16].   
Despite these inherent limitations, the MA-10 cell line was chosen as a model for 
the current work because they coexpress insl3 and nur77 [6] and are functionally capable 
of responding to gondadotropin stimulation [16].  The overall objective of this research 
was to further characterize the factors that regulate insl3 production in the Leydig cell, by 
determining whether LH/CG induces insl3 production, confirming the effect of LH/CG 
on nur77 and then deciphering which signal transduction pathway(s) may be involved in 
regulating both insl3 and nur77 mRNA abundance.  Additionally, the mRNA abundance 
of the steroidogenic enzymes cyp17 and 3β-hsd was measured in response to LH/CG and 
the second messenger cAMP, to determine the functional status of the MA-10 cell as a 
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steroidogenic model.  MA-10 cells were also supplemented with exogenous testosterone 
to assess the autocrine effects of testosterone on both insl3 and nur77 abundance. 
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 2.2 Materials and Methods 
 
All reagents were purchased from Sigma Aldrich, unless otherwise indicated. 
 
Cell Culture  
 
MA-10 cells were generously provided by Dr. Mario Ascoli (University of Iowa, 
IA).  Prior to plating, 25cm2 cell culture flasks (Corning) were incubated with 0.1% 
gelatin solution (0.5g DIFCO bactogelatin, 500 ml Ca2+/Mg2+-free PBS) covering the 
growth area of the flask for 45 minutes at room temperature.  The gelatin solution was 
aspirated before plating.  Cells were maintained at 37°C in 5% CO2 in DMEM F12 
growth medium (pH 7.7) supplemented with 20mM HEPES, 15% horse serum 
(Invitrogen), 1% penicillin/streptomycin and 1% amphotericin B.  Within each 
experiment, cells were cultured with horse serum from the same lot.   
Human CG (Cell Sciences), 8-bromo cAMP, (Bu)2-cAMP and testosterone were 
included in media at concentrations indicated in figure legends.  For signal transduction 
pathway inhibitor experiments, MA-10 cells were pre-treated with one of the following 
inhibitors for 3 hours: 10µM H 89-dihydrochloride (H89; PKA inhibitor), 10nM 
wortmannin (WORT; PKB inhibitor), 10µg/ml pseudohypericin (PH; PKC inhibitor) or 
50µM PD90859 (PD; MAPK inhibitor)(Santa Cruz Biotechnology).  The pre-treatment 
growth media was then replaced with growth media containing either 0 or 100ng/ml hCG 
and the inhibitor for an additional 1 or 3 hours before RNA extraction, as indicated in 
Figure 2A/B.     
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RNA Extraction and Reverse Transcription 
Cells were released from flasks through incubation with 0.5X trypsin/EDTA 
solution and subsequently washed in 5 ml media by centrifugation.  Total RNA was 
extracted from the resulting cell pellet using the RNeasy® Mini Kit (Qiagen).  The RNA 
concentration of each sample was determined by spectrophotometry.  First strand cDNA 
was synthesized from 1 µg RNA using the iScript™ Select cDNA Synthesis Kit (BioRad), 
with either oligo dT or random primers.   
 
Quantitative Real Time Polymerase Chain Reaction 
Quantitative polymerase chain reaction (qPCR) was used to quantify target gene 
mRNA abundance.  Gene-specific primers (Table 1) were used to amplify target genes in 
cDNA samples using an Applied Biosystems 7500 Fast Real-Time PCR System (1 cycle 
at 95°C for 20 seconds, 50 cycles at 95°C for 3 seconds, and 1 cycle at 60°C for 30 
seconds) with Fast SYBR Green Master Mix (Applied Biosystems, Foster City, CA).  
The specificity of each primer set was verified by dissociation curve.  To further validate 
the insl3 primers, the qPCR product was gel purified using the Qiagen Qiaquick® Gel 
Extraction Kit per the manufacturer’s protocol and sequenced by Sequetech (Mountain 
View, CA).  Target mRNA abundance values were obtained using the 2-∆∆Ct equation 
using the abundance of TATA binding protein (TBP) mRNA as an internal control to 
correct for reverse transcription efficiency.  
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Statistical Analysis 
All qPCR data were analyzed using the general linear model in Statistical Analysis 
Software (SAS Carey, NC), with all treatments being compared to the control.  The 
abundance of target mRNA is reported as the mean ± SEM (n=3).   Means were 
considered significantly different at P<0.05..
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Table 1:  Gene specific primers for quantitative polymerase chain reaction.  Accession numbers indicate the GenBank 
sequence that was referenced to design primers using IDT DNA Technologies PrimerQuest software.  Primers were validated 
and chosen based upon their scores in both NetPrimer and Beacon Designer software programs. 
Gene  Primer sequence (5’-3’) Product 
Size 
Accession number 
Mus 
musculus 
insl3 
Sense 
Antisense 
CCTCCTGGCTATGTCATTGCAACA 
CTGTGGTCCTTGCTTACTGCGAT 
85bp NM_013564.6 
Mus 
musculus 
nur77 
Sense 
Antisense 
AGACCTGTTGCTAGAGTCTGCCTT 
TCAATCCAATCACCAAAGCCACGG 
147bp NM_010444.2 
Mus 
musculus 
cyp17 
Sense 
Antisense 
TGCTCATTCCACACAAGGCTAACA 
TAAACCGATCTGGCTGGTCCCATT 
132bp NM_007809.3 
Mus 
musculus 
 3β-hsd1 
Sense 
Antisense 
TCAGCCACCACCATCTCAGACTTT 
AGCCGCTCAGTTCAGAATGTAGGA 
81bp NM_008293.3 
Mus 
musculus 
 tbp 
Sense 
Antisense 
ACACTCAGTTACAGGTGGCAGCAT 
CAAGTAGCAGCACAGAGCAAGCAA 
130bp NM_013684 
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2.3 Results  
 
Treatment with 100ng/ml hCG did not have a significant effect on insl3 mRNA 
abundance at 1, 2, or 3 hours (Figure 1A).  The ability of MA-10 cells to respond to 
gonadotropin stimulation was confirmed by measuring nur77 mRNA abundance in hCG-
treated samples.  There was a significant but transient increase in nur77 mRNA 
abundance at 1h of treatment, while at 2 and 3h, nur77 mRNA abundance was 
significantly lower than that of the control (Figure 1B).   
To determine which signal transduction pathway the LHR uses to regulate insl3 
and nur77 production by the Leydig cell, MA-10 cells were subjected to a 3 hour pre-
treatment period with inhibitors of four pathways that have been shown to be utilized by 
the LHR: cAMP/PKA, PI3K/PKB, PKC and MAPK signal transduction pathways.  
Following pre-treatment, the cells were treated with media containing the inhibitor with 
which the sample was pre-treated and 100ng/ml hCG for 1 and 3h.  The abundance of 
insl3 mRNA was not increased in response to hCG alone.  Inhibition of any one pathway 
did not affect insl3 mRNA levels, though there was a significant increase in insl3 mRNA 
abundance when the PI3K/PKB pathway was inhibited in the presence of hCG for 3h 
(Figure 2A).  The abundance of nur77 mRNA was significantly increased in response to 
hCG treatment for one hour as before, though this induction was not affected by the 
addition of any single pathway inhibitor (Figure 2B).  The pre-treatment period alone did 
not affect insl3 or nur77 mRNA abundance (data not shown). 
Though it has been shown that cAMP increases insl3 mRNA in the MA-10 cell 
line [6], inhibition of the cAMP/PKA pathway with or without hCG did not affect the 
abundance of insl3 mRNA in the MA-10 cell line (Figure 2A).  Treatment with 8-bromo 
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cAMP for 6 hours significantly decreased insl3 mRNA abundance, while (Bu)2-cAMP 
did not affect insl3 mRNA abundance (Figure 3A), while both cAMP analogs 
significantly increased nur77 mRNA abundance after 6 hours of treatment (Figure 3B).  
Because cAMP is a second messenger and therefore may have an effect in a shorter time 
frame, cells were treated with 0.5mM (Bu)2-cAMP for 0.5, 1, 2 and 4 hours.  The 
abundance of insl3 mRNA was still unaffected, even at these shorter time points (Figure 
4A), while nur77 mRNA abundance was significantly increased at all time points (Figure 
4B).  
To assess the status is the steroidogenic machinery of the MA-10 cell line, the 
abundance of 3β-hsd and cyp17 mRNA was quantified in response to hCG and cAMP.  
Neither 100ng/ml hCG or 0.5mM cAMP at any time point have any effect on 3β-hsd 
mRNA abundance (Figure 5A,C).   
It has been shown that MA-10 cells do not express cyp17 mRNA and therefore do 
not convert progesterone to testosterone during steroidogenesis [15].  Contrary to these 
findings, cyp17 mRNA was not only present, but significantly increased in response to 
100ng/ml hCG at 1, 2, and 3 hours and 0.5mM (Bu)2-cAMP at 2 and 4 hours (Figure 
5B,D).  
The ability of this cell line to respond to gonadotropin stimulation was confirmed 
by the significant increase in nur77 mRNA in response to hCG.  Others have shown that 
testosterone increases insl3 mRNA in the MA-10 cell [13].  Because this cell line is 
purported to lack CYP17 activity and therefore produces progesterone instead of 
testosterone, the potential autocrine actions of testosterone on insl3 production would not 
be apparent in the MA-10 cell line.  Therefore, MA-10 cells were supplemented with 
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exogenous testosterone.  While testosterone alone did not affect nur77 mRNA 
abundance, hCG alone significantly increased nur77 mRNA abundance at both 1 and 3 
hours.  Additionally, the combination of hCG and testosterone significantly increased 
nur77 mRNA abundance at both 1 and 3 hours (Figure 6A).   In accordance with the 
initial treatment of MA-10 cells with hCG, insl3 mRNA abundance remained unchanged 
at all time points.   Interestingly, treatment of MA-10 cells with 15nM testosterone did 
not affect insl3 mRNA abundance, nor did the combination of hCG and testosterone 
(Figure 6B). 
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Figure 1: The effect of hCG on insl3 and nur77 mRNA abundance:  Insl3 (A) and 
nur77 (B) mRNA abundance in MA-10 cells treated with 100ng/ml hCG for 1, 2 and 3h.  
Values represent the mean ± SEM (n=3); an asterisk indicates a statistically significant 
difference from the control (P<0.05).
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Figure 2: The effect of hCG and pathway inhibition on insl3 and nur77 mRNA 
abundance:  Insl3 (A) and nur77 (B) mRNA abundance in MA-10 cells treated with 
10µM H 89-dihydrochloride (H89; PKA inhibitor), 10nM wortmannin (WORT; PKB 
inhibitor), 10µg/ml pseudohypericin (PH; PKC inhibitor) or 50µM PD90859 (PD; 
MAPK inhibitor) and 100ng/ml hCG for 1 and 3h.  Values represent the mean ± SEM 
(n=3); an asterisk indicates a statistically significant difference from the control (P<0.05). 
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Figure 3: The effect of cAMP analogs on insl3 and nur77 mRNA abundance: Insl3 
(A) and nur77 (B) mRNA abundance in MA-10 cells treated with 0.6mM 8-bromo cAMP 
or 0.6mM (Bu)2-cAMP for 6 hours.  Values represent the mean ± SEM (n=3); an asterisk 
indicates a statistically significant difference from the control (P<0.05).
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Figure 4: The effect of (Bu)2-cAMP on insl3 and nur77 mRNA abundance at four 
different time points: Insl3 (A) and nur77 (B) mRNA abundance in MA-10 cells treated 
with 0.5mM (Bu)2-cAMP for 0.5, 1, 2, and 4h (C).  Values represent the mean ± SEM 
(n=3); an asterisk indicates a statistically significant difference from the control (P<0.05).
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Figure 5: The effect of hCG and cAMP on 3β-hsd and cyp17 mRNA abundance: 3β-
hsd and cyp17 mRNA abundance in MA-10 cells treated with 100ng/ml hCG for 1, 2 and 
3h (A,C) or 0.5mM (Bu)2-cAMP for 0.5, 1, 2 and 4h (B,D).  Values represent the mean ± 
SEM (n=3); an asterisk indicates a statistically significant difference from the control 
(P<0.05). 
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Figure 6: The effect of hCG and testosterone on insl3 and nur77 mRNA abundance: 
Insl3 (A) and nur77 (B) mRNA abundance in MA-10 cells treated with 100ng/ml hCG 
and 15nM testosterone in a 2x2 factorial design for 1 and 3h.  Values represent the mean 
± SEM (n=3); an asterisk indicates a statistically significant difference from the control 
(P<0.05). 
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2.4 Discussion 
 Though there was considerable evidence in the literature implicating LH as the 
stimulus of INSL3 production, treatment with hCG did not affect insl3 mRNA abundance 
in the MA-10 cell line.  These data indicate either an inability of the MA-10 cell to 
respond to gonadotropin stimulation or that there is another means by which insl3 is 
regulated.  The robust increase in nur77 mRNA abundance in response to hCG indicates 
that these cells are indeed capable of responding to gonadotropin stimulation, suggesting 
an alternative mechanism that regulates insl3 production in the Leydig cell. 
 Additional evidence to support an alternative stimulus of insl3 production comes 
from the observation that individual inhibition of the LHR-linked cAMP/PKA, PKC or 
MAPK pathways in the presence of hCG did not have an effect on insl3 mRNA levels at 
1 or 3 hours.  The exception is the significant increase in insl3 mRNA abundance 
observed in the presence of hCG and wortmannin for 3h, indicative of hCG being capable 
of inducing insl3 after 3h, but only when the PI3K/PKB pathway is inhibited.   Multiple 
pathways could be responsible for activating or repressing insl3 production.  These data 
indicate that the PI3K/PKB pathway may have a suppressive effect on insl3.  
Individually, The cAMP/PKA, PKC or MAPK kinase pathways do not seem to play a 
role in insl3 regulation, though they may work in concert and with other pathways that 
were not included as a part of this work.  Inhibition of multiple pathways at once may 
provide further insight into the combinatorial role of these pathways in insl3 production.  
  Though hCG treatment for one hour consistently and significantly increased 
nur77 mRNA abundance, the pathway through which hCG works to produce this effect 
remains unclear.  The addition of any single pathway inhibitor did not affect the ability of 
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hCG to induce nur77 production.  As with insl3, these data indicate that there may be 
multiple pathways, potentially including some that were not included in this experiment, 
that regulate nur77 mRNA abundance in the Leydig cell.  A similar experiment was 
conducted in the K28 Leydig cell line, where cells were treated for 1h with 200ng/ml LH 
and either 10uM H89 (PKA inhibitor), 100nM bisindolylmaleimide I (PKC inhibitor) or 
10nM wortmannin (PKB inhibitor).  Nur77 mRNA abundance was assessed by Northern 
blot.  LH treatment alone significantly increased nur77 mRNA, concurrent with the 
results presented above.  However, when PKA was inhibited in the presence of LH, the 
LH- mediated induction of Nur77 mRNA was decreased by 73%.  Further, inhibition of 
PKC and PKB in the presence of LH resulted in a 76% and 70% reduction in nur77 
mRNA, respectively [10].  It is important to note that in the present work, the same PKA 
and PKB inhibitors were utilized at the same concentration, with divergent results from 
those in the literature.  Though an effect of pathway inhibition was observed in the K28 
Leydig cell line and not in the present work in the MA-10 cell line, what is consistent is 
the indication that multiple pathways regulate nur77 mRNA abundance in the Leydig 
cell.    
 Inhibition of the cAMP/PKA pathway did not affect insl3 or nur77 mRNA 
abundance.  Similarly, treatment of MA-10 cells with cAMP analogs did not induce 
insl3; specifically, treatment with 0.5mM (Bu)2-cAMP for 4h failed to increase insl3 
mRNA abundance. These results are contrary to that of Robert et al. (2006), though the 
same cell line and experimental design was utilized.  Interestingly, though both cAMP 
analogs at all time points significantly increased nur77 mRNA, inhibition of the 
cAMP/PKA pathway did not abrogate the hCG-induced increase in nur77 abundance.  
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While the cAMP-mediated increase in nur77 mRNA implicates the cAMP/PKA pathway 
in nur77 regulation, the inhibition of that pathway does not corroborate those results, 
suggesting that the cAMP/PKA pathway may not be the only pathway involved in the 
hCG-regulation of nur77 mRNA abundance.  
 The abundance of 3β-hsd mRNA remained unchanged in the presence of hCG 
and cAMP.  Though 3β-HSD activity, mRNA and protein abundance have been shown to 
increase in primary Leydig cell cultures in response to LH and cAMP, these effects were 
not realized until 24h of treatment [17], suggesting that the effects of hCG and cAMP on 
3β-hsd mRNA abundance may not be observed until a later time point.  Additionally, in 
primary Leydig cell cultures, 3β-hsd mRNA seems to be expressed at relatively high 
basal levels in the absence of either LH or cAMP [18]. 
Though it has been shown that MA-10 cells do not express cyp17 [15], the current 
data indicate otherwise.  Not only do these cells express cyp17, but also it is inducible in 
the presence of hCG and cAMP.  Though it was surprising to detect cyp17 mRNA in 
MA-10 cells, the induction of cyp17 in the presence of both hCG and cAMP is consistent 
with previous work in primary mouse Leydig cells, which indicated that CYP17 enzyme 
activity was basically undetectable in the absence of LH or cAMP, but when cells were 
treated with LH or cAMP, there was a time-dependent increase in CYP17 activity over 
the course of 5-7 days [19-21].  The present data indicate that a similar time-dependent 
increase in cyp17 mRNA may be observed over a matter of hours.    
It has been shown that treatment of MA-10 cells with testosterone significantly 
increases insl3 mRNA abundance after 36h [13].  In the present work, 12h treatment of 
MA-10 cells with testosterone or the combination of hCG and testosterone did not affect 
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insl3 mRNA abundance.  Testosterone may still play a role in insl3 production through 
an autocrine action on the Leydig cell, though perhaps over a longer period of time.  
Treatment with hCG and the combination of hCG and testosterone significantly increased 
nur77 mRNA abundance at one and three hours.  The primary stimulus for this increase 
seems to be hCG, as testosterone alone did not have an effect and hCG treatment alone 
resulted in an increase similar to that observed with the combination of hCG and 
testosterone.  
The response of the MA-10 cell line to hCG is inconsistent relative to the 
magnitude of response exhibited by nur77 and the induction of nur77 at times greater 
than one hour.  These inconsistencies between experiments may be due to the fact that it 
was not possible to maintain all cells for all experiments in serum from the same lot.  
Serum is a common requirement in cell culture media and provides growth and adhesion 
factors, minerals, lipids and hormones to the cells.  Typically, these components are 
present in unknown concentrations and there is a high degree of variability between 
batches of serum.  To negate these issues, some cell lines can be maintained in serum free 
media, which is formulated to contain all necessary factors in known concentrations for 
that cell line [22].  Another method of eliminating variability in cell response due to 
serum factors is to serum-starve the cells for a designated amount of time before applying 
treatment to remove the effects of the serum on the cells before assessing the cellular 
response to treatment.  Though not presented here, all attempts to culture MA-10 cells 
without serum resulted in detachment and significant cell death, so serum starvation was 
not a viable protocol for these cells.  To minimize the potential effects of serum in the 
present work, all individual experiments were conducted with serum from the same lot 
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and though the serum lot may have differed between experiments, it never differed within 
experiments.  Therefore, the inherent differences between serum lots may account for 
some variability between experiments.  
The inter-experiment variability may also be due to the fact that fresh hCG was 
purchased for each experiment in an effort to correct for a potential decline in hormone 
activity due to prolonged storage in solution.  The inconsistencies between experiments 
may be a manifestation of inherent differences in the hCG preparations used for each 
experiment.  Therefore, the parameters of each experiment were as similar as possible, 
though they were not identical because of the inability to culture MA-10 cells in serum-
free media and the requirement for fresh hCG for each experiment. 
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2.5 Conclusions and Implications 
Cell models, particularly primary cell isolates and immortalized cell lines, are 
widely used to assess cellular systems and individual cell function.  Though primary 
cultures potentially bear greater similarity to cells in vivo, they can be laborious to isolate, 
difficult to maintain in culture, may contain other cell types and possess the inherent 
limitation of a finite number of cell divisions.  
Immortalized cell lines are homologous populations of cells, easier to maintain in 
culture and theoretically capable of an infinite number of divisions.  The immortality of 
these cells is due to either their tumorogenic lineage or transformation with an 
immortalizing antigen.  The homology of a cell line allows for the assessment of the 
effects of a treatment on only the cell type of interest, without the complication of other 
cell types and signals that are present in tissue samples.  This homology does, however 
remove an individual cell system from the potentially more biologically relevant in vivo 
context, where cells are regulated by cell-to-cell interactions, other cell types and other 
signals [22].  Further, using a tumorogenic cell line removes the model even further from 
the natural context, as these cell lines can exhibit differential expression of any number of 
genes.  
Prevalent in the literature as a tool for investigating steroidogenesis, LH/CG 
actions, INSL3 regulation and other Leydig cell functions, the MA-10 cell line is a 
widely accepted and utilized Leydig cell line isolated from a murine Leydig cell tumor.   
Comparison with other Leydig cell lines and primary cells has revealed that the MA-10 
cell line most closely mimics in vivo Leydig cell expression of several key genes, 
including insl3, nur77 and sf-1 [6].  
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The shortcomings of the MA-10 cell line, such as the decrease in LHR 
abundance, proliferative capacity, adherence to cell culture surfaces and the alleged lack 
of a critical steroidogenic enzyme seem to be manageable issues.  MA-10 cells are still 
functionally capable of responding to gonadotropin stimulation, plating on gelatin rescues 
proliferation and attachment problems and insl3 production is not dependent on the 
aforementioned steroidogenic enzyme.  Therefore, in this context, the MA-10 cell line 
appeared to be useful model to study insl3 regulation.   
Further experimentation with this cell line suggested otherwise.  The results of 
this work conflict with previously published data in terms of the insl3 response to cAMP 
and the presence of cyp17 mRNA.  Because of the detrimental effects of serum starving 
this cell line, eliminating serum as a contributing factor of inter-experiment variability is 
impractical.  This poses a problem for assessing the response of the MA-10 cell line to 
hormone stimulation, because of the unknown factors present in serum that may enhance 
or abrogate a response by the cell to any additional treatment.  The inconsistencies with 
previous work along with the inability to correct for the variability between experiments 
suggest that this cell line may no longer be a suitable model of Leydig cell function as it 
has been in previous years. 
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2.6 Reconciliation and Future investigations  
 Though LH was implicated in the literature by numerous studies as a potential 
regulator of insl3 production by the Leydig cell, it was surprising that the current data 
indicated otherwise.  This coupled with the discrepancy between these and published data 
regarding the cAMP-mediated increase in insl3 mRNA abundance may be accounted for 
by the numerous regulatory factors that have yet to be identified in this system.   Though 
the current work does not necessarily provide direct empirical evidence to support the 
presence of other factors, it does indicate that there may be several other features of the 
insl3 production process that may warrant further investigation.  
 Though the MA-10 cell line has been shown to lack CYP17 mRNA and activity, 
the current work indicates that at the very least, cyp17 mRNA is present and inducible in 
the presence of hCG and cAMP.  If this cell line has differentially expressed this enzyme 
over time and regained the ability to express CYP17, the expression of any number of 
other genes may have also changed.  For example, it has been shown that Nur77 is a 
downstream effector of the cAMP/PKA pathway and must be dephosphorylated at 
several serine residues to allow and promote the binding of this transcription factor to the 
promoters that it regulates [11, 23, 24].  However, the specific mechanism by which this 
dephosphorylation is regulated and the identity of the protein phosphatase that modulates 
this activation of Nur77 remains to be identified.  If the regain of cyp17 expression by the 
MA-10 cell line coincided with a loss in the ability to express the protein phosphatase 
responsible for activating Nur77, hCG and cAMP may not be able to induce an increase 
insl3 mRNA because of the lack of Nur77 activation.  
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 In addition to the possibility that the MA-10 cells exhibit a different expression 
pattern of an unknown number of genes than Leydig cells in vivo, the presence of a 
repressor that interacts with the insl3 promoter may account for lack of induction of insl3 
in the presence of both cAMP and hCG.  In this case, if the stimulus required to remove 
the repressor is not expressed by the MA-10 cell line, the repressor would continue to 
inhibit transcription and the mRNA abundance of insl3 would not increase in response to 
cAMP or hCG.  Though a repressor that specifically regulates insl3 production has not 
been identified, inhibition of Nur77 action may also have an effect on insl3 mRNA 
abundance.  The androgen receptor corepressor-19 kDa (ARR19) has been shown to 
inhibit the transactivation of Nur77 in MA-10 cells by interacting with Nur77 and thereby 
preventing Nur77 from binding to the coactivator steroid receptor coactivator (SRC-1).  
This was demonstrated by transfecting MA-10 cells with Nur77 response element-driven 
reporter vectors and Nur77 and ARR19 expression vectors.  In this context, the presence 
of ARR19 resulted in the repression of Nur77 transactivation in a dose-dependent 
manner.  Further, when MA-10 cells were cotransfected with CYP17, StAR and 3β-HSD 
reporter constructs and Nur77 and ARR19 expression vectors, ARR19 inhibited Nur77-
induced promoter activity of each of the tested steroidogenic enzyme genes.  ARR19 was 
further shown regulate Nur77 transactivation by physically interacting with this 
transcription factor and preventing Nur77 from binding SRC-1 [25]. 
The evidence indicating that Nur77 binds to and is capable of activating the insl3 
promoter in the MA-10 cell line was obtained by cotransfecting cells with an insl3 
promoter-driven reporter construct and a Nur77 expression vector [6].  In this context, 
Nur77 may be able activate the insl3 promoter only because Nur77 is over expressed and 
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therefore may have the ability to overwhelm any repressors present in the MA-10 cells at 
that time.  While these data provide a useful starting point for understanding the complex 
process of insl3 regulation, the use of a singular expression vector further removes the 
data from the biologically relevant in vivo context, where all regulatory factors would 
theoretically be present in natural amounts relative to one another.  In order to accurately 
assess the factors that regulate insl3 production through transfection assays, expression 
vectors of all pertinent factors would need to be utilized, whether they be coactivators or 
repressive in nature.  In the current work, the abundance of the factors that regulate insl3 
mRNA abundance would only be determined by the cells themselves, as no exogenous 
expression vectors were utilized.  It may be that because Nur77 was not overexpressed in 
this case, any repressors that were present could not be overwhelmed by the endogenous 
amounts of Nur77.   Further, because only the abundance of nur77 mRNA was 
determined and not that of all other pertinent factors, whether or not those factors are 
produced by the MA-10 cell line remains to be determined.  
These data and those of the current work indicate that there may be numerous 
layers of regulatory mechanisms at work in the Nur77-regulated production of insl3 by 
the MA-10 Leydig cell.  Investigating the role of these factors in insl3 regulation in this 
cell line and in a primary Leydig cell line or in vivo would be critical to validating the 
MA-10 cell line as an appropriate Leydig cell model and gaining a more comprehensive 
understanding of the complex network of factors that control this system.   
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